Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Ductless Fume Hoods

March 21, 2011 8:22 am | Product Releases | Comments

The PURAIR 5 Ductless Fume Hoods from Air Science USA feature a high level of operator protection where routine work is being carried out. The units exceed OSHA, ANSI and all relevant international standards.

TOPICS:

Jacketed Reactor

March 21, 2011 8:20 am | Product Releases | Comments

Syrris will launch the Globe jacketed reactor platform at the Spring ACS Expo. This chemical reactor enables vessels from 50 mL to 5 L to use a common clamp, lid, circulator and stand.

TOPICS:

AB SCIEX And Alturas Working on DBS Analysis

March 21, 2011 8:03 am | News | Comments

AB SCIEX and Alturas Analytics Inc., a provider of LC/MS contract research services, announced a collaboration to accelerate the adoption of dried blood spot analysis for drug discovery & development.

TOPICS:
Advertisement

Quanta Collaborating with IDT on miRNA

March 21, 2011 7:55 am | News | Comments

Quanta Biosciences has developed hundreds of assays for quantifying microRNAs, and has entered into a partnership with Integrated DNA Technologies to custom manufacture them.

TOPICS:

Prophylactic Antibiotics Lowers Risk in ICU

March 21, 2011 7:53 am | News | Comments

Giving critically ill patients antibiotics as a preventive measure significantly reduces the risk of infection with highly resistant microorganisms, according to the largest prospective study of topical preventive antibiotics in intensive care unit.

TOPICS:

Organic Nanoparticle Uses Heat Against Tumors

March 21, 2011 7:50 am | News | Comments

A team of scientists have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

TOPICS:

LNA Compounds Can Inhibit Disease Families

March 21, 2011 7:44 am | News | Comments

A new study demonstrates that Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases.

TOPICS:

New Vaccine Designed to Aid Patients with COPD

March 21, 2011 7:37 am | News | Comments

Scientists at Melbourne biotechnology company Hunter Immunology have developed a treatment for Chronic Obstructive Pulmonary Disorder, or COPD, which is being trialled on up to 340 patients at major hospitals around the country.

TOPICS:
Advertisement

EU Approves Gilenya

March 21, 2011 7:34 am | News | Comments

Swiss drug maker Novartis AG says it has received European Union approval to sell its oral multiple sclerosis medication Gilenya in the 27-nation bloc.

TOPICS:

New Plaintiff in BMS Bribery Suit

March 21, 2011 7:32 am | News | Comments

California has joined a whistleblower lawsuit that claims Bristol-Myers Squibb Co. bribed doctors to prescribe its drugs, costing insurers perhaps millions of dollars in the largest alleged health care fraud case ever handled by the state.

TOPICS:

Anavex Granted Alzheimer's Trial Approval

March 21, 2011 7:22 am | News | Comments

Anavex Life Sciences Corp. announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority.

TOPICS:

Mucosis Begins Trial for Vaccine Targeted at Elderly

March 21, 2011 7:17 am | News | Comments

Mucosis B.V. announced the start of a Phase 1 clinical study with its lead product FluGEM, a novel improved influenza vaccine for the elderly. It is the vaccine candidate based on Mimopath, a platform for developing more potent vaccines.

TOPICS:

FDA Approves Oxford BioMedica Trial Application

March 21, 2011 7:14 am | News | Comments

The US Food and Drug Administration has approved Oxford BioMedica plc's investigational new drug application for the Phase 1/2a clinical development of StarGen, a novel gene-based treatment for Stargardt disease.

TOPICS:

CTI Starts PIX-R Lymphoma Trial

March 21, 2011 7:08 am | News | Comments

Cell Therapeutics, Inc. announced that it has initiated a randomized trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

TOPICS:

Positive Results in Vismodegib Carcinoma Trial

March 21, 2011 7:04 am | News | Comments

Genentech announced that a Phase 2 clinical study of its hedgehog pathway inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma, a particularly severe and debilitating form of skin cancer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading